Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)

Study Overview
=================
Brief Summary
-----------------
The investigators group uses an individualised radiation dose approach in which the dose is escalated up to pre-defined tissue constraints (see below). The target dose to the tumor is 69Gy. However, this dose cannot be reached in approximately 30% of the patients, even with an IMRT (Intensity Modulated Radiotherapy) technique, because the MLD (Mean Lung Dose) constraint of 20Gy is reached at a TTD (Total Treatment Dose) below 69Gy. In this study, the investigators will adapt the treatment by performing a new (PET)-CT at day 12 during radiotherapy and in case of a decreased Planning Target Volume (PTV), the dose mey be increased.

Detailed Description
-----------------
Eligible patients will receive concurrent chemo-radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to an MLD (Mean Lung Dose) of 20 +/- 1Gy, irrespective of lung function. Other dose constraints: spinal cord max: 54Gy, brachial plexus (Dmax):66Gy. In concurrent with chemotherapy, radiotherapy will be delivered as follows: First three weeks /30 fractions:twice-daily fractions of 1.5Gy, with 8h to 10h as interfraction interval, 5 days per week. Total dose: 45Gy/30 fractions. Thereafter: once-daily fractions of 2.0Gy, 5 days per week until the target dose has been reached. In sequential or radiotherapy alone schedules, twice-daily 1.8Gy with an interfraction interval of at least 8h will be delivered. The radiation doses will be specified according to ICRU 50. Lung density corrections will be applied, as well as all standard QA procedures. Technical requirements are the same as in standard practice at MAASTRO clinic. Chemotherapy schedules allowed: 1-2 cycles induction chemotherapy: any third generation schedule is allowed. The type will be registered. Concurrent part: (day 1=first day of radiotherapy) cisplatin-vinorelbine cisplatin-docetaxel cisplatin-etoposide cisplatin-pemetrexed in non-squamous histologies Q3 week; 3 cycles When the calculated creatinin clearance is less than 60 ml/min, cisplatin may be substituted for carboplatin. In case the TTD(Total Treatment Dose)=69Gy cannot be reached because of a limiting MLD, a FDG-PET-CT will be performed at day 12 during radiotherapy. GTV's (Gross Tmor Volume), CTV's (Clinical Target Volume) and PTV's (Planning Target Volume) will be delineated and a new plan calculated. The endpoint will be the proportion of patients that will receive 69Gy.

Official Title
-----------------
Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Other: Radiotherapy and concurrent chemo-therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histological or cytological proven NSCLC UICC stage I-III, or solitary metastases (<6), which are amendable for radical local treatment Performance status 0-2 IMRT technique Exclusion Criteria: Not NSCLC of mixed NSCLC and other histologies (e.g. small cell carcinoma) Stage IV, except for solitary (<6) metastases Performance status 3 or more

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Radiotherapy<br> | Other: Radiotherapy and concurrent chemo-therapy<br>* Radiotherapy and concurrent chemo-therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients able to receive 69Gy as TTD |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 3 months | 
| Progression free survival |  | 3 months | 
| Dyspnea (CTCAE 4.0) |  | 3 months | 
| Dysphagia (CTCAE 4.0) |  | 3 months | 
| Patterns of recurrence |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Radiotherapy, NSCLC, Stage II-III non-small cell lung cancer